243 related articles for article (PubMed ID: 24202965)
1. The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway.
Park J; Ko YS; Yoon J; Kim MA; Park JW; Kim WH; Choi Y; Kim JH; Cheon Y; Lee BL
Gastric Cancer; 2014; 17(3):423-30. PubMed ID: 24202965
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
[TBL] [Abstract][Full Text] [Related]
3. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
Chock KL; Allison JM; Shimizu Y; ElShamy WM
Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
[TBL] [Abstract][Full Text] [Related]
4. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
5. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
6. FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.
Park J; Choi Y; Ko YS; Kim Y; Pyo JS; Jang BG; Kim MA; Lee JS; Chang MS; Park JW; Lee BL
Cancer Res Treat; 2018 Jan; 50(1):239-254. PubMed ID: 28343375
[TBL] [Abstract][Full Text] [Related]
7. p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax.
Kim CW; Lu JN; Go SI; Jung JH; Yi SM; Jeong JH; Hah YS; Han MS; Park JW; Lee WS; Min YJ
Int J Oncol; 2013 Nov; 43(5):1495-502. PubMed ID: 23970333
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of FAM3B Promotes Cisplatin Resistance in Gastric Cancer by Inducing Epithelial-Mesenchymal Transition.
Song C; Duan C
Med Sci Monit; 2020 May; 26():e921002. PubMed ID: 32442162
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
10. Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients.
Nakamura M; Tsuji N; Asanuma K; Kobayashi D; Yagihashi A; Hirata K; Torigoe T; Sato N; Watanabe N
Cancer Sci; 2004 Jan; 95(1):44-51. PubMed ID: 14720326
[TBL] [Abstract][Full Text] [Related]
11. Apoptin-derived peptide reverses cisplatin resistance in gastric cancer through the PI3K-AKT signaling pathway.
Zhou D; Liu W; Liang S; Sun B; Liu A; Cui Z; Han X; Yuan L
Cancer Med; 2018 Apr; 7(4):1369-1383. PubMed ID: 29522284
[TBL] [Abstract][Full Text] [Related]
12. Curcumin induces apoptosis in pancreatic cancer cells through the induction of forkhead box O1 and inhibition of the PI3K/Akt pathway.
Zhao Z; Li C; Xi H; Gao Y; Xu D
Mol Med Rep; 2015 Oct; 12(4):5415-22. PubMed ID: 26166196
[TBL] [Abstract][Full Text] [Related]
13. PEA‑15 contributes to the clinicopathology and AKT‑regulated cisplatin resistance in gastric cancer.
Jiang X; Zhang C; Li W; Jiang D; Wei Z; Lv M; Xie X; Sun X
Oncol Rep; 2019 Mar; 41(3):1949-1959. PubMed ID: 30569123
[TBL] [Abstract][Full Text] [Related]
14. Forkhead Box Protein C2 Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in Cisplatin-Resistant Human Ovarian Cancer Cell Line (SKOV3/CDDP).
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(3):1098-110. PubMed ID: 27562816
[TBL] [Abstract][Full Text] [Related]
15. FOXO1 and FOXO3a sensitize non-small-cell lung cancer cells to cisplatin-induced apoptosis independent of Bim.
Sun T; Zhang J; Deng B; Fan X; Long T; Jin H; Tao S; Kang P; Tan Q
Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(12):1348-1359. PubMed ID: 33167006
[TBL] [Abstract][Full Text] [Related]
16. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
[TBL] [Abstract][Full Text] [Related]
17. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway.
Wang XJ; Feng CW; Li M
Mol Cell Biochem; 2013 Aug; 380(1-2):57-66. PubMed ID: 23625205
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
[TBL] [Abstract][Full Text] [Related]
19. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
20. Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression.
Su J; Zhang F; Li X; Liu Z
Biochem Biophys Res Commun; 2019 Jun; 514(2):510-517. PubMed ID: 31056260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
